Reviva Pharmaceuticals Holdings Inc
Reviva Pharmaceuticals Holdings, Inc. RVPH | 0.00 |
Reviva Pharmaceuticals Holdings Inc RVPH.OQ RVPH.O is expected to show no change in quarterly revenue when it reports results on May 13 (estimated) for the period ending March 31 2026
LSEG's mean analyst estimate for Reviva Pharmaceuticals Holdings Inc is for a loss of 62 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts had risen by about 12.5% in the last three months.
Wall Street's median 12-month price target for Reviva Pharmaceuticals Holdings Inc is $30.00, about 3,404.7% above its last closing price of $0.86
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING |
STARMINESMARTESTIMATE® |
LSEG IBES ESTIMATE |
ACTUAL |
BEAT, MET, MISSED |
SURPRISE % |
Dec. 31 2025 |
-1.20 |
-1.17 |
|||
Sep. 30 2025 |
-1.76 |
-1.94 |
-1.20 |
Beat |
38.2 |
Jun. 30 2025 |
-2.30 |
-2.20 |
-2.40 |
Missed |
-9.1 |
Mar. 31 2025 |
-3.60 |
-3.65 |
-2.60 |
Beat |
28.8 |
Dec. 31 2024 |
-4.39 |
-4.30 |
-3.00 |
Beat |
30.2 |
Sep. 30 2024 |
-5.45 |
-4.92 |
-5.00 |
Missed |
-1.6 |
Jun. 30 2024 |
-5.81 |
-5.80 |
-5.20 |
Beat |
10.3 |
Mar. 31 2024 |
-7.30 |
-7.53 |
-5.00 |
Beat |
33.6 |
This summary was machine generated May 11 at 11:36 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)